Identification of clinical predictors of flare in systemic lupus erythematosus patients: A 24-month prospective cohort study

Rheumatology (United Kingdom)

Volumn 53, Issue 1, 2014, Pages 85-89

  Inês, Luís ^a,b   Duarte, Cátia ^a   Silva, Rosário Santos ^c   Teixeira, Ana Sofia ^d   Fonseca, Fernando Pereira ^a,b   Da Silva, José António P ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^c Hospital Distrital da Figueira da Foz   (Portugal)

^d Centro Hospitalar Cova da Beira   (Portugal)

Author keywords

Cohort study; Outcomes research; Prognosis; Prospective study; Systemic lupus erythematosus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SLEDAI; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

COHORT STUDY; OUTCOMES RESEARCH; PROGNOSIS; PROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; BIOPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890924153     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket322     Document Type: Article

References (22)

1. Duarte C, Couto M, Inês L et al. Epidemiology of SLE. In: Lahita RG, ed. Systemic lupus erythematosus. London: Elsevier, 2010:673-96.
2. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20-8.
3. Bertsias GK, Tektonidou M, Amoura Z et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771-82.
4. Furie R, Petri M, Zamani O et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
5. Nikpour M, Urowitz MB, Ibañez D et al. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009;61:1152-8.
6. Buján S, Ordi-Ros J, Paredes J et al. Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. Ann Rheum Dis 2003;62:859-65.
7. Ahern JM, Liu CC, Kao AH et al. Biomarkers for systemic lupus erythematosus. Transl Res 2012;159:326-42.
8. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
9. Gladman DD, Ibanez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002;29:288-91.
10. Yee CS, Farewell VT, Isenberg DA et al. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology 2011;50:982-8.
11. Ibañez D, Gladman DD, Urowitz MB. Adjusted mean SystemicLupusErythematosusDiseaseActivityIndex-2K is a predictor of outcome in SLE. J Rheumatol 2005;32:824-7.
12. Isenberg DA, Allen E, Farewell V et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis 2011;70:54-9.
13. Lee J, Tan CS, Chia KS. A practical guide for multivariate analysis of dichotomous outcomes. Ann Acad Med Singapore 2009;38:714-9.
14. McNutt LA, Wu C, Xue X et al. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003;157:940-3.
15. Schmidt CO, Kohlmann T. When to use the odds ratio or the relative risk? Int J Public Health 2008;53:155-7.
16. Houssiau FA, D'Cruz D, Sangle S et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-9.
17. Shinjo SK, Bonfá E, Wojdyla D et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010;62:855-62.
18. Lopez R, Davidson JE, Beeby MD et al. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology 2012;51:491-8.
19. Nossent J, Kiss E, Rozman B et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010;19:949-56.
20. Hersh AO, von Scheven E, Yazdany J et al. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum 2009;61:13-20.
21. Tucker LB, Uribe AG, Fernández M et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus 2008;17:314-22.
22. Watson L, Leone V, Pilkington C et al. Juvenile-onset SLE; disease activity, severity and damage-the UK JSLE Cohort Study. Arthritis Rheum 2012;64:2356-65.